Intra-Cellular Therapies, Inc. (ITCI)

NASDAQ: ITCI · Real-Time Price · USD
85.64
+2.29 (2.75%)
Nov 20, 2024, 4:00 PM EST - Market closed
2.75%
Market Cap 9.08B
Revenue (ttm) 613.73M
Net Income (ttm) -86.37M
Shares Out 106.02M
EPS (ttm) -0.86
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 384,196
Open 83.35
Previous Close 83.35
Day's Range 82.77 - 86.36
52-Week Range 58.14 - 93.45
Beta 0.97
Analysts Strong Buy
Price Target 97.67 (+14.05%)
Earnings Date Oct 30, 2024

About ITCI

Intra-Cellular Therapies, Inc., a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States. The company offers CAPLYTA for the treatment of schizophrenia and bipolar depression in adults. It is also involved in developing Lumateperone, which is in Phase 3 clinical trial for the treatment of vario... [Read more]

Sector Healthcare
Founded 2002
Employees 610
Stock Exchange NASDAQ
Ticker Symbol ITCI
Full Company Profile

Financial Performance

In 2023, Intra-Cellular Therapies's revenue was $464.37 million, an increase of 85.51% compared to the previous year's $250.31 million. Losses were -$139.67 million, -45.49% less than in 2022.

Financial Statements

Analyst Forecast

According to 12 analysts, the average rating for ITCI stock is "Strong Buy." The 12-month stock price forecast is $97.67, which is an increase of 14.05% from the latest price.

Price Target
$97.67
(14.05% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Intra-Cellular Therapies to Participate in Three Upcoming Investor Conferences

BEDMINSTER, N.J., Nov. 19, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for cent...

1 day ago - GlobeNewsWire

Intra-Cellular Therapies Announces Presentations at the 2024 Psych Congress and NEI Congress

Presentations include results from two pivotal studies (Studies 501 and 502) evaluating lumateperone as an adjunctive therapy to antidepressants for the treatment of major depressive disorder (MDD)

13 days ago - GlobeNewsWire

Intra-Cellular's schizophrenia drug meets main goal in late-stage trial

Intra-Cellular Therapies said on Tuesday its drug to prevent relapses in schizophrenia patients met the main goal of a late-stage trial.

15 days ago - Reuters

Intra-Cellular Therapies, Inc. (ITCI) Q3 2024 Earnings Call Transcript

Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Q3 2024 Earnings Conference Call October 30, 2024 8:30 AM ET Company Participants Juan Sanchez - VP, Corporate Communications & IR Sharon Mates - Founder,...

21 days ago - Seeking Alpha

Intra-Cellular Therapies Reports Third Quarter 2024 Financial Results, Provides Corporate Update and Raises 2024 Caplyta Sales Guidance

CAPLYTA Q3 2024 net product sales were   $175.2 million, compared to $125.8 million for the same period in 2023, representing a 39% increase

21 days ago - GlobeNewsWire

Intra-Cellular Therapies to Host Third Quarter 2024 Financial Results Conference Call and Webcast

NEW YORK, Oct. 17, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nerv...

4 weeks ago - GlobeNewsWire

Intra-Cellular Therapies Announces Presentations at the 2024 European College of Neuropsychopharmacology Congress

Oral and poster presentations of results from Study 501 evaluating lumateperone 42 mg as an adjunctive therapy to antidepressants for the treatment of major depressive disorder (MDD)

2 months ago - GlobeNewsWire

Intra-Cellular Therapies to Present at Three Upcoming Investor Conferences

NEW YORK, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nerv...

3 months ago - GlobeNewsWire

Intra-Cellular Therapies to Present at the Canaccord Genuity 44th Annual Growth Conference

NEW YORK, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nerv...

3 months ago - GlobeNewsWire

Intra-Cellular Therapies, Inc. (ITCI) Q2 2024 Earnings Call Transcript

Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Q2 2024 Earnings Conference Call August 7, 2024 8:30 AM ET Company Participants Juan Sanchez - Vice President of Corporate Communications & Investor Relat...

3 months ago - Seeking Alpha

Intra-Cellular Therapies Announces Appointment of Sanjeev Narula as Chief Financial Officer

NEW YORK, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nerv...

3 months ago - GlobeNewsWire

Intra-Cellular Therapies Reports Second Quarter 2024 Financial Results, Provides Corporate Update and Raises 2024 CAPLYTA Sales Guidance

CAPLYTA Q2 2024 net product sales were   $161.3 million, compared to $110.1 million for the same period in 2023, representing a 46% increase

3 months ago - GlobeNewsWire

Intra-Cellular Therapies to Host Second Quarter 2024 Financial Results Conference Call and Webcast

NEW YORK, July 24, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nerv...

4 months ago - GlobeNewsWire

Intra-Cellular Brightens MDD Outlook With Caplyta Success

Caplyta (lumateperone) shows significant promise as an adjunctive treatment for Major Depressive Disorder. Caplyta's unique pharmacological profile targeting serotonin, dopamine, and glutamate pathway...

5 months ago - Seeking Alpha

Intra-Cellular Therapies' Highlights Successful Data From Second Depression Study

Tuesday, Intra-Cellular Therapies Inc ITCI released topline results from Study 502 evaluating lumateperone 42 mg as an adjunctive therapy to antidepressants for the treatment of major depressive disor...

5 months ago - Benzinga

Intra-Cellular Therapies Announces Positive Topline Results in Second Phase 3 Trial Evaluating Lumateperone as Adjunctive Therapy in Patients with Major Depressive Disorder

In Study 502, lumateperone 42 mg achieved statistically significant and clinically meaningful results in both the primary and the key secondary endpoints

5 months ago - GlobeNewsWire

Intra-Cellular Therapies to Present at the 45th Annual Goldman Sachs Global Healthcare Conference

NEW YORK, June 10, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nerv...

5 months ago - GlobeNewsWire

Intra-Cellular Therapies to Present at the Jefferies Global Healthcare Conference

NEW YORK, May 29, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervo...

6 months ago - GlobeNewsWire

Intra-Cellular Therapies Highlights Data Presentations at the American Society of Clinical Psychopharmacology Annual Meeting

NEW YORK, May 23, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervo...

6 months ago - GlobeNewsWire

Intra-Cellular Therapies, Inc. (ITCI) Q1 2024 Earnings Call Transcript

Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Q1 2024 Earnings Conference Call May 7, 2024 8:30 AM ET Company Participants Juan Sanchez - Vice President of Corporate Communications and Investor Relati...

7 months ago - Seeking Alpha

Intra-Cellular Therapies Reports First Quarter 2024 Financial Results

CAPLYTA Q1 2024 net product sales were   $144.8 million , compared to $94.7 million for the same period in 2023 , representing a 53% increase

7 months ago - GlobeNewsWire

Intra-Cellular Therapies to Host First Quarter 2024 Financial Results Conference Call and Webcast

NEW YORK, April 30, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central ner...

7 months ago - GlobeNewsWire

Intra-Cellular Therapies: Positive MDD Data And Commercial Momentum Make It A Buy

The share price reaction of Intra-Cellular Therapies was not as strong as expected after the positive phase 3 results of Caplyta in major depressive disorder. Positive MDD results represent another de...

7 months ago - Seeking Alpha

Intra-Cellular Therapies Announces Closing of $575 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares

NEW YORK, April 24, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI) (“Intra-Cellular Therapies”), a biopharmaceutical company focused on the development and commercialization of...

7 months ago - GlobeNewsWire

Intra-Cellular Therapies Prices Public Offering of Common Stock

NEW YORK, April 17, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI) (“Intra-Cellular Therapies”), a biopharmaceutical company focused on the development and commercialization of...

7 months ago - GlobeNewsWire